



Tel: +91 22 33321600 Fax: +91 22 2439 3700

www.bdo.in

BDO Valuation Advisory LLP The Ruby, Level 9, North West Wing Senapati Bapat Marg, Dadar (W) Mumbai 400028, India

Ref. No.: LM/Feb2-121/2022 February 02, 2022

To

The Board of Directors
Shalimar Paints Limited
4th Floor, Plot No. - 50

Sector 32, Gurugram, 122001

Haryana, India.

Dear Sir(s)/Madam(s),

Sub: Valuation Report to Determine Issue and Conversion Price of Optionally Convertible Debentures ("OCDs") of Shalimar Paints Limited to Comply with the Provisions of the Companies Act, 2013.

We, BDO Valuation Advisory LLP ('BDO Val' or 'We' or 'Us'), have been appointed vide engagement letter dated January 14, 2022 bearing its reference number LM/Jan142/2022 by Shalimar Paints Limited ("You" or "Shalimar" or "the Client" or "the Company") in relation to determination of issue and conversion price of Optionally Convertible Debentures ("OCDs") proposed to be issued and allotted. The OCDs are optionally convertible into equity shares of the Company if the proposed investor decides to exercise the option to convert the OCDs into equity share(s) as per the terms of proposed issuance of the OCDs as mutually agreed between the Company and the proposed investor. Should the proposed investor decide to exercise its aforementioned option, the OCDs will be converted into equity shares at a predetermined price ("Conversion Price").

We understand that the Company is proposing to issue its OCDs to an identified investor on preferential issue and private placement basis ("the Proposed Transaction") and the Client wants us to determine issue and Conversion Price of OCDs as per the Companies Act, 2013 and rules made thereunder as applicable.

We are pleased to present herewith our report on the same ("Report"). We enclose our Report providing our opinion as on January 11, 2022 ("Valuation Date"). The Report details the valuation methodologies, calculations and conclusions with respect to this valuation.

We believe that our analysis must be considered as a whole. Selecting portions of our analysis or the factors we considered, without considering all factors and analysis together could create a misleading view of the process underlying the valuation conclusions.

BDO Valuation Advisory LLP, an Indian limited liability partnership firm, with LLP Identity No. AAN9463, is a member of BDO International Limited, a UK company limited by guarantee and forms part of the International BDO network of independent member



The preparation of a valuation is a complex process and is not necessarily susceptible to partial analysis or summary description. Any attempt to do so could lead to undue emphasis on any particular factor or analysis.

This letter should be read in conjunction with the attached Report. Should you require further information or clarifications, please feel free to contact us.

For BDO Valuation Advisory LLP

IBBI No.: IBBI/RV-E/02/2019/103

Lata R Gujar More

IBBI No.: IBBI/RV/06/2018/10488

Partner

Strictly Confidential Page 3 of 22



Table of Contents

1.	Brief Background of the Company	5
2.	Purpose of Valuation	7
3.	Terms of Engagement	7
4.	Caveats, Limitations and Disclaimers	8
5.	Sources of Information	11
6.	Procedures Adopted	12
7.	Proposed Terms of Issue	13
8.	Determination of Price for Issue and Conversion of OCDs	14
9.	Valuation of OCDs of Shalimar	18
10.	Conversion Price	19
11.	Conclusion	20
12.	Annexure	21

Page **4** of **22**



1. Brief Background of the Company

- 1.1. Shalimar Paints Limited is engaged in the business of manufacturing, selling and distribution of paints, coatings and providing related services. It has pan-India presence through its marketing offices in all major states in India.
- 1.2. The Corporate Identification Number ("CIN") of the Company is L24222HR1902PLC065611 and its registered office address is Stainless Centre, 4th floor, Plot no.- 50, Sector 32, Gurugram, 122001, Haryana.
- 1.3. The equity shares of Shalimar are listed on the National Stock Exchange of India Limited ("NSE") and the BSE Limited ("BSE").
- 1.4. The Company has manufacturing facilities located at Howrah, Nasik, Sikandrabad & Chennai (Gummidipundi) for products i.e. Paints that includes Emulsion, Distemper and Primer. The plantwise installed capacity of the Company is as follows:

Installed Production Capacity (in KLPA)

Plant Name	FY21
Howrah Plant	-
Nasik Plant*	21,600
Sikandarabad Plant	23,400
Gummidipundi Plant	24,000
Total	69,000

^{*}The Company has increased capacity of Nasik Plant from 1,800KLPA in FY 19 to 21,600KLPA in FY21

- 1.5. The Company is one of the oldest paint manufacturing brands founded during pre-independence era in Howrah West Bengal and seen many management changes. In 1989 the current promoters bought the Company. The Company has gone through the toughest time since 2014 due to fire in Howrah plant in 2014 and Nasik plant in 2016.
- 1.6. The shareholding pattern of as on December 31, 2021 is as follows:

Particulars	Number of Shares in Mn	%
Promoter & Promoter Group	28.8	53.1%
Public	25.5	46.9%
Total	54.3	100.0%

Strictly Confidential Page 5 of 22



1.7. Key Past Financial Matrix

				INR Mn
Revenue	FY19	FY20	FY21	Sep 21 (6M)
Revenue from Operations (INR Mn)	2,876.2	3,438.5	3,255.6	1,561.0
Year or Year Growth	3.6%	19.6%	(5.3%)	(4.1%)
Reported EBITDA (INR Mn)	(757.0)	(254.5)	88.2	(190.7)
EBITDA (%)	(26.3%)	(7.4%)	2.7%	(12.2%)
PAT (INR Mn)	(817.4)	(381.8)	(498.6)	(362.7)
PAT (%)	(28.4%)	(11.1%)	(15.3%)	(23.2%)

The Company's financial performance is erratic in last 3 years. EBITDA was marginally positive in FY21 on account of improvement in revenue in last two quarters of FY21. There was an improvement in revenue from operation in first half of FY22 as compared to FY21, however Margin is negative due to increase in raw material prices.

The summary of capacity utilization of the Company is tabulated below:

Particulars	FY19	FY20	FY21
Installed Capacity Utilization (KLPA)	48,000	62,400	69,000
Total Production (KLPA)	26,475	31,212	28,604
Capacity Utilization	55.2%	50.0%	41.5%

Key Past Financial Matrix

				INR Mn
Balance Sheet as at	March 31, 19	March 31, 20	March 31, 21	September 30, 21
Equity	107.3	108.6	108.6	108.6
Other Equity *	2,945.7	2,620.1	2,122.1	1,760.3
Net Worth	3,053.0	2,728.7	2,230.7	1,868.9
Term Loan including Working	1,523.8	1,207.7	1,305.4	1,510.9
Capital Loan	1,525.0	1,207.7	1,303.4	1,510.9

^{*}Other Equity includes Securities Premium Reserve, shares options outstanding, general reserves, retained earnings and other comprehensive income.

As depicted above, the financial position of the Company is becoming weak as the borrowings are increasing and networth is diminishing y-o-y.

<<this space is intentionally left blank>>

Strictly Confidential Page 6 of 22



2. Purpose of Valuation

- 2.1. The Company is proposing to issue OCDs to an identified investor on preferential issue and private placement basis and appointed us vide letter dated January 14, 2022 bearing its reference number LM/Jan142/2022 to determine issue and Conversion Price of OCDs to comply with the provisions of the Companies Act, 2013 and rules made thereunder as applicable.
- 2.2. The Client's management ("the Management") has informed us to consider the Valuation Date for current valuation exercise as January 11, 2022 ("Valuation Date"). Therefore, the cut-off date for all information, including market data, has been considered till January 10, 2022.

3. Terms of Engagement

Context and Purpose

3.1. BDO Val has been appointed to determine the issue and Conversion Price of OCDs as per Companies Act, 2013 and rules made thereunder as applicable. This valuation exercise and Report are solely for the purpose mentioned in the Report.

Restricted Audience

- 3.2. This Report and the information contained herein are absolutely confidential and are intended for the use of the Client only for applicable provisions and for sharing it with the proposed investor. The results of our valuation analysis and our Report cannot be used or relied by the Company for any other purpose or by any other party for any purpose whatsoever.
- 3.3. This Report will be placed before Board of Directors of Shalimar and intended only for their sole use and information only. To the extent mandatorily required under applicable laws of India, this Report maybe produced before judicial, regulatory or government authorities, in connection with the proposed issue of OCDs (including with SEBI and stock exchanges). We are not responsible to any other person or party for any decision of such person or party based on this Report. Any person or party intending to provide finance/ invest in the shares/ business of the Company or its subsidiaries, associates, joint ventures shall do so after seeking their own professional advice and after carrying out their own due diligence procedures to ensure that they are making an informed decision. If any person/ party (other than the Client) chooses to place reliance upon any matters included in the Report, they shall do so at their own risk and without recourse to BDO Val.
- 3.4. It is hereby notified that usage, reproduction, distribution, circulation, copying or otherwise quoting of this Report or any part thereof, except for the purpose as set out earlier in this Report, without our prior written consent, is not permitted, unless there is a statutory or a regulatory requirement to do so.

Strictly Confidential Page 7 of 22



3.5. Without limiting the foregoing, we understand that the Client may be required to share this Report with Registrar of Companies, regulatory/ statutory authorities, professional advisors of the Client, upload on its website, allow inspection by shareholders, and share it with the proposed allottee/ investor. We hereby give consent to such disclosure of this Report, on the basis that we owe responsibility only to the Client that has engaged us, under the terms of the engagement, and no other person; and that, to the fullest extent permitted by law, we accept no responsibility or liability to any other party, in connection with this Report. It is clarified that reference to this Report in any document and/or filing with Ministry of Corporate Affairs, SEBI and stock exchanges etc., in connection with the Proposed Transaction, shall not be deemed to be an acceptance by us of any responsibility or liability to any person/ party other than the Client.

4. Caveats, Limitations and Disclaimers

- 4.1. This Report is to be read in totality, and not in parts, in conjunction with the relevant documents referred to therein.
- 4.2. This Report, its contents, and the analysis herein are specific to (i) the purpose of valuation agreed as per the terms of our engagement, (ii) the Report date and (iii) based on the data detailed in the section Sources of Information. The Management have represented that the business activities of the Company have been carried out in the normal and ordinary course till the Report date and that no material changes are expected in their respective operations and financial position to occur upto the Report date.
- 4.3. We were provided with sufficient information and time to make our opinion for this valuation exercise. However, our opinion may change if any material information is not disclosed / hidden from us during our valuation exercise.
- 4.4. The scope of the assignment did not include performing audit tests for the purpose of expressing an opinion on the fairness or accuracy of any financial or analytical information that was used during the course of the work. Accordingly, we express no audit opinion or any other form of assurance on this information on behalf of the Company. The assignment did not involve us to conduct the financial or technical feasibility study. We have not done any independent technical valuation or appraisal or due diligence or legal title search of the assets or liabilities of the Company and have considered them at the value as disclosed by the Company in their regulatory filings or in submissions, oral or written, made to us.
- 4.5. Further, this Report is based on the extant regulatory environment and the financial, economic, monetary and business/market conditions, and the information made available to us or used by us up to the date hereof, which are dynamic in nature and may change in future, thereby impacting the valuation of the Company. Subsequent developments in the aforementioned conditions may affect this Report and the assumptions made in preparing this Report and we shall not be obliged

Strictly Confidential Page 8 of 22



to update, review or reaffirm this Report if the information provided to us changes. Further events occurring after the date hereof may affect this Report and the assumptions used in preparing it, and we do not assume any obligation to update, revise or reaffirm this Report.

- 4.6. We have no present or planned future interest in the Company or any of their group entities.
- 4.7. The recommendation contained herein is not intended to represent value at any time other than the Valuation Date.
- 4.8. This Report is subject to the laws of India.
- 4.9. The fee for this engagement is not contingent upon the outcome of the Report.
- 4.10. In rendering this Report, we have not provided legal, regulatory, tax, accounting or actuarial advice and accordingly we do not assume any responsibility or liability in respect thereof.
- 4.11. This Report is based on the information received from the sources mentioned herein and discussions with the representatives of the Company. We have assumed that no information has been withheld that could have influenced the purpose of our Report.
- 4.12. We have assumed and relied upon the truth, accuracy and completeness of the information, data and financial terms provided to us or used by us, we have assumed that the same are not misleading and do not assume or accept any liability or responsibility for any independent verification of such information or any independent technical valuation or appraisal of any of the assets, operations or liabilities of the Company. Nothing has come to our knowledge to indicate that the material provided to us was mis-stated or incorrect or would not afford reasonable grounds upon which to base our Report.
- 4.13. For the present valuation exercise, we have also relied upon information available in the public domain; however, the accuracy and timeliness of the same has not been independently verified by us.
- 4.14. In addition, we do not take any responsibility for any changes in the information used by us to arrive at our conclusion as set out here in which may occur subsequent to the date of our Report or by virtue of fact that the details provided to us are incorrect or inaccurate.
- 4.15. The valuation has been arrived based on our analysis. Any transaction price may however be significantly different and would depend on the negotiating ability and motivations of the respective buyers and sellers in the transaction.

Strictly Confidential Page 9 of 22



- 4.16. Our scope is limited to recommendation of price for issue and Conversion Price of the OCDs. The Report should not be construed as, our opinion or certifying the compliance of the Proposed Transaction with the provisions of any law including Foreign Exchange Management Act, 1999, taxation related laws, capital market related laws, any accounting, taxation or legal implications or issues arising from Proposed Transaction.
- 4.17. The Report assumes that the Company comply fully with relevant laws and regulations applicable in all their areas of operation unless otherwise stated and that the Company will be managed in competent and responsible manner. Further, except as specifically stated to the contrary, this Report has given no consideration to matters of legal nature, including issues of legal title and compliance with local laws, litigation and other contingent liabilities that are not recorded in the financial statements of the Company.
- 4.18. This Report does not look into the business/commercial reasons behind the Proposed Transaction nor the likely benefits arising out of the same. Similarly, it does not address the relative merits of the Proposed Transaction as compared with any other alternative business transaction or any other alternatives, whether or not such alternatives could be achieved or are available. The assessment of commercial and investment merits in the Company is sole responsibility of the investors of the Company and we don't express opinion on the suitability or otherwise of entering into any financial or other transactions with the Company.
- 4.19. Valuation and determination of a fair value is not a precise science and the conclusions arrived at in many cases will be subjective and dependent on the exercise of individual judgment. There is therefore no indisputable single value. While we have provided an assessment of the value based on an analysis of information available to us and within the scope of our engagement, others may place a different opinion.
- 4.20. Whilst all reasonable care has been taken to ensure that the factual statements in the Report are accurate, neither us, nor any of our partners, officers or employees shall in any way be liable or responsible either directly or indirectly for the contents stated herein. Accordingly, we make no representation or warranty, express or implied, in respect of the completeness, authenticity or accuracy of such factual statements. We expressly disclaim any and all liabilities, which may arise based upon the information used in this Report.
- 4.21. We owe responsibility to only the Board of Directors of the Client and nobody else. We will not be liable for any losses, claims, damages or liabilities arising out of the actions taken, omissions of or advice given by any other party to the Company. In no event shall we be liable for any loss, damages, cost or expenses arising in any way from fraudulent acts, misrepresentations or willful default on part of the Company, their directors, employees or agents. In the particular

Strictly Confidential Page 10 of 22



circumstances of this case, our liability, if any (in contract or under statute or otherwise) for any economic loss or damage arising out of or in connection with this engagement, howsoever the loss or damage caused, shall be limited to the amount of fees actually received by us from the Client as laid out in the engagement letter, for such valuation work.

- 4.22. We do not accept any liability to any third party in relation to the issue of this Report. It is understood that this analysis does not represent a fairness opinion. This Report is not a substitute for the third party's own due diligence/ appraisal/ enquiries/ independent advice that the third party should undertake for his purpose.
- 4.23. This Report does not in any manner address the prices at which equity shares of Shalimar will trade following the announcement and/or implementation of the Proposed Transaction and we express no opinion or recommendation as to how the shareholders of the Company should vote at the shareholders' meeting(s) to be held in connection with the Proposed Transaction.
- 4.24. The recommendation(s) rendered in this Report only represent our recommendation(s) based upon information furnished by the Company (or its representatives) and other sources and the said recommendation(s) shall be considered to be in the nature of non-binding advice, (our recommendation will however not be used for advising anybody to take buy or sell decision, for which specific opinion needs to be taken from expert advisors).
- 4.25. Further, after declaration of COVID-19 as a pandemic by World Health Organization had caused a widespread disruption in businesses as well as on financial markets in India and globally alike. Our assumptions for the valuation is surrounded by this unprecedented uncertainty across all the industries and sectors including the time period over which these circumstances could prevail. The valuation assumptions, the underlying projections and the outcome of the valuation analysis could materially change as a result of the continued or increased uncertainty around the prevalence of COVID-19 circumstances and hence a reliance on our valuation must be placed considering these unprecedented circumstances.

5. Sources of Information

For the purpose of undertaking this valuation exercise, we have relied on the following sources of information provided by the Management and representatives of the Company:

- 5.1. Terms of proposed issue of OCDs;
- 5.2. Audited Consolidated financial statements of Shalimar for the financial year ending 31st of March ("FY") 2018 to 2021;
- 5.3. Limited Review Financial Statement of Shalimar as on September 30, 2021;
- 5.4. Information provided by leading database sources and available in public domain; and
- 5.5. Other relevant data and information provided to us, whether in oral or physical form or in soft copy, and discussions with the representatives of the Client.

Strictly Confidential Page 11 of 22



6. Procedures Adopted

- 6.1. In connection with this exercise, we have adopted the following procedures to carry out the valuation:
 - Requested and received the historical financials as well as qualitative information of the Company and its operations;
 - Obtained data available in public domain;
 - Discussion with the Client (over call) with regard to the Company:
 - Understood the business and fundamental factors that affect its earning-generating capability and historical financials;
 - Considered the International Valuation Standards issued by International Valuation Standards Council ("IVS"), along with the required provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and as amended from time to time (referred as "ICDR Regulations").
 - Selection of appropriate internationally accepted valuation methodologies after careful deliberations. Our valuation and this Report are based on the premise of "going concern" value. Any change in the valuation base, or the premise could have significant impact on the outcome of the valuation exercise, and therefore, this Report.
 - Determination of price for issue and Conversion Price of OCDs of the Company as on the Valuation Date.
 - The Client has been provided with the opportunity to review the draft Report as part of our standard practice to make sure that factual inaccuracies/omissions of the information are avoided in our final Report; and
 - Issue of final Report.

<<this space is intentionally left blank>>

Strictly Confidential Page 12 of 22



7. Proposed Terms of Issue

7.1. The proposed terms of OCDs to be issued by Shalimar are as follows:

Particulars	Terms
Issue Price	INR 180.00 per OCD
Coupon	9.0% per annum
Coupon Terms	Paid on quarterly basis
Embedded Options	
	The coupton shall be calculated from the date of allotment of the Investor OCDs until the
Coupon Payment	date of conversion or redemption as the case may be. The coupon amount shall be payable
Сопрон Раушент	in cash each quarter commencing from the date of allotment up to and including the date of
	redemption or conversion, as the case may be
Conversion Option	The Investor, at its sole discretion, has the right (but not the obligation) to convert the OCDs
Conversion Price	INR 180.00 per OCD
Redemption Price	INR 180.00 per OCD
Maximum Option Tenure	18 months from the date of allotment
Mandatory Redemption Date	End of 18 months from the date of allotment

<<this space is intentionally left blank>>

Strictly Confidential Page 13 of 22



8. Determination of Price for Issue and Conversion of OCDs

- 8.1. It is pertinent to note that the valuation of any company or its undertaking or its securities or its assets is inherently imprecise and is subject to certain uncertainties and contingencies, all of which are difficult to predict and are beyond our control. In performing our analysis, we made numerous assumptions with respect to industry performance and general business and economic conditions, many of which are beyond the control of the Company. In addition, this valuation will fluctuate with changes in prevailing market conditions, and prospects, financial and otherwise, of the Company, and other factors which generally influence the valuation of Company and their assets.
- 8.2. The application of any particular method of valuation depends on the purpose for which the valuation is done. Although different values may exist for different purposes, it cannot be too strongly emphasized that a valuer can only arrive at one value for one purpose. Our choice of methodology of valuation has been arrived at using usual and conventional methodologies adopted for transactions of a similar nature and our reasonable judgment, in an independent and bona fide manner based on our previous experience of assignments of a similar nature.
- 8.3. It may be noted that BDO Val is enrolled with IOV Registered Valuers Foundation, which has recommended to follow IVS for undertaking valuation. We have given due cognizance to the same in carrying out the valuation exercise. We have considered the International Valuation Standards issued by International Valuation Standards Council ("IVS"). Further we have also referred the specific valuation requirement / guidelines of the Companies Act, 2013 and ICDR Regulations as applicable.
- 8.4. The fair value of proposed issue of OCDs is required to be determined as on the Valuation Date under applicable provisions of Companies Act, 2013. Further as per the Rule 13(2)(h) of the Companies (Share Capital and Debentures) Rules, 2014, conversion price of the OCDs need to be determined and the relevant sub-rule is as below:
 - (h) where convertible securities are offered on a preferential basis with an option to apply for and get equity shares allotted, the price of the resultant shares pursuant to conversion shall be determined-
 - (i) either upfront at the time when the offer of convertible securities is made, on the basis of valuation report of the registered valuer given at the stage of such offer, or
 - (ii) at the time, which shall not be earlier than thirty days to the date when the holder of convertible security becomes entitled to apply for shares, on the basis of valuation report of the registered valuer given not earlier than sixty days of the date when the holder of convertible security becomes entitled to apply for shares.

Strictly Confidential Page 14 of 22



Provided that the company shall take a decision on sub-clauses (i) or (ii) at the time of offer of convertible security itself and make such disclosure under sub-clause (v) of clause (d) of sub-rule (2) of this rule.

- 8.5. The equity shares of Shalimar are listed on the NSE and BSE. Therefore, to arrive at the price for issue and conversion of OCDs, ICDR Regulations have also been referred/considered during the valuation exercise, and these are as set out below.
- 8.6. Regulation 163(4) of ICDR Regulations related to convertible securities, is reproduced below:
 - (4) The special resolution shall specify the relevant date on the basis of which price of the equity shares to be allotted on conversion or exchange of convertible securities shall be calculated.
- 8.7. Regulation 164(1) of the ICDR Regulations related to pricing guidelines for frequently traded equity shares as follows:
 - (4) If the equity shares of the issuer have been listed on a recognized stock exchange for a period of twenty six weeks or more as on the relevant date, the price of the equity shares to be allotted pursuant to the preferential issue shall be not less than higher of the following:
 - a. the average of the weekly high and low of the volume weighted average price of the related equity shares quoted on the recognized stock exchange during the twenty-six weeks preceding the relevant date; or
 - b. the average of the weekly high and low of the volume weighted average prices of the related equity shares quoted on a recognized stock exchange during the two weeks preceding the relevant date.
- 8.8. As per Regulation 164(5) "frequently traded shares" means the shares of the issuer, in which the traded turnover on any recognized stock exchange during the twelve calendar months preceding the relevant date, is at least ten per cent of the total number of shares of such class of shares of the issuer.
- 8.9. As per Regulation 161 the 'relevant date' in case of preferential issue of equity shares is as below:

 Relevant Date:
 - a. the date thirty days prior to the date on which the meeting of shareholders is held to consider the proposed preferential issue.
 - b. in case of a preferential issue of convertible securities, either the relevant date referred to in clause (a) of this regulation or a date thirty days prior to the date on which the holders of the convertible securities become entitled to apply for the equity share.

Strictly Confidential Page 15 of 22



- Further for OCDs, the Management has informed us that the relevant date shall be the date thirty days prior to the date on which the meeting of shareholders is held to consider the proposed preferential issue (i.e. February 10, 2022) and therefore the relevant date is January 11, 2022.
- 8.10. The ICDR Regulations are silent about determination of floor price of OCDs. However, it is pertinent to note that equity shares will be issued on conversion of OCDs. Hence, considering all above-mentioned regulations, equity share price has been arrived referring Regulation 164(1) of ICDR Regulations for determining the floor price of conversion of OCDs into equity shares.
- 8.11. We understand that the OCDs have two embedded options i.e., conversion option and redemption option (straight bond). The right to select the option of conversion is available with the holder of OCDs i.e., the proposed allottee. Such right of conversion may be exercised by the proposed allottee at its sole discretion and in accordance with the OCD Terms.
 - 8.11.1 The OCDs will be issued at INR 180.0/- each. The OCDs may be converted into equity shares at INR 180.0 per equity share, at the sole option and discretion of the investor in accordance with the terms of the issuance of the OCDs, but not later than 18 months from the date of allotment of the OCDs. If not opted for conversion, each OCD shall be automatically redeemed at the end of 18 months from the date of allotment of the OCDs. The equity shares arising out of conversion of the OCDs will rank pari passu in all respects with the then outstanding equity shares of the Company. Thus, for arriving at fair value for issue and conversion of OCDs to be issued, we have considered Black Scholes Model for valuation of call option on equity shares of the company and Straight Bond Value Method for valuation of debenture.
 - 8.11.2 Hence, Valuation of proposed to be issued OCDs = value of call option + value of straight bond.

8.12. Equity Valuation

- As stated above, the equity shares of the Company are listed on the NSE and BSE. There is regular transaction in the equity shares with reasonable volumes. The pricing regulations as prescribed for equity shares as per Regulation 164 (1) of the ICDR Regulations is considered for arriving at the equity share price as per market price method.

Strictly Confidential Page 16 of 22



8.13. Black Scholes Model

- 8.13.1. When the price process is continuous, i.e., price changes becomes smaller as time periods get shorter, the binomial model for pricing options converges on the Black Scholes model.
- 8.13.2. The model, named after its co-creators, Fischer Black and Myron Scholes, allows us to estimate the value of any option using a small number of inputs and has been shown to be remarkably robust in valuing many listed options.
- 8.13.3. The option price and the stock price depend on the same underlying source of uncertainty.
- 8.13.4. We can form a portfolio consisting of the stock and the option which eliminates this source of uncertainty.
- 8.13.5. The portfolio is instantaneously riskless and must instantaneously earn the risk-free rate.
- 8.13.6. This leads to the Black-Scholes differential equation. Any security whose price is dependent on the stock price satisfies the differential equation.
- 8.13.7. The particular security being valued is determined by the boundary conditions of the differential equation.
- 8.13.8. In a forward contract, the boundary condition is f = S K when t = T
 - a) The solution to the equation is f = S K e r (T t) When the call option contract matures, the payoff is:
 - b) Solving the equation with the end condition, we obtain the Black-Scholes formula (on the right) where:
 - c) S = Current value of the underlying asset
 - d) K = Strike price of the option
 - e) t = Life to expiration of the option
 - f) r = Riskless interest rate corresponding to the life of the option
 - g) s2 = Variance in the In(value) of the underlying asset

$$c = S_0 N(d_1) - K e^{-rT} N(d_2)$$

$$p = K e^{-rT} N(-d_2) - S_0 N(-d_1)$$
where
$$d_1 = \frac{\ln(S_0 / K) + (r + \sigma^2 / 2)T}{\sigma \sqrt{T}}$$

$$d_2 = \frac{\ln(S_0 / K) + (r - \sigma^2 / 2)T}{\sigma \sqrt{T}} = d_1 - \sigma \sqrt{T}$$

8.14. Valuation of Straight Bonds

8.14.1 Valuation of Straight Bonds will involve calculating the bond's cash flow or the present value of a bond's future payment.

Strictly Confidential Page 17 of 22



8.14.2 The nature of straight bond part in OCDs being same, we have adopted the above approach for valuation of straight bond.

9. Valuation of OCDs of Shalimar

9.1. Valuation of Equity (S)

- 9.1.1 The equity shares Shalimar are frequently traded on the NSE & BSE in terms of Regulation 164(5) of ICDR Regulations, with maximum volume recorded at NSE for the specific period i.e., January 01, 2021 to December 31, 2021 (Refer Annexure I).
- 9.1.2 We have considered the equity share prices quoted on the NSE for determining the equity value of the Company. The value per share of the Company as per Regulation 164 (1) of ICDR Regulations, is INR 113.43/- as below:

Particulars	Price per share	Annexure
26 Weeks (A)	102.17	Ш
2 Weeks (B)	113.43	- "
Higher of "A" or "B"	113.43	-

9.2. Valuation of Call Option as per Black Scholes Model

- Stock Price: We have considered the stock price of INR 113.43, as determined above.
- Exercise Price: The exercise price is the conversion price in the current case i.e,
 INR 180.0. The conversion price is the price per share at which a convertible security, such as corporate bonds or preferred shares, can be converted into common stock.
- Expected Volatility of the Share price: Volatility is a measure of the amount by which a price
 has fluctuated or is expected to fluctuate during a period. The measure of volatility used in
 the Black Scholes Model is the annualized standard deviation of the continuously
 compounded rates of return on the stock over a period of time. In the present case, we have
 considered volatility of 51.8%.
- Dividend Yield: For present valuation exercise, we have considered Dividend Yield of 0.0% as the Company has not issued any dividend in the past 1.5 years.
- Life to Expiration (time to maturity/expected life of options) is the period for which call option is expected to live. The OCDs are convertible into equity shares of the Company at any time at the sole discretion of the holder, but not later than 18 months from the date of allotment of the OCDs. Therefore, we have considered life of call option as 1.5 years (i.e., 18 months).
- Risk-free Interest Rate: The risk-free interest rate has been considered based on the zero-coupon yield curve for Government Securities (as quoted on the Clearing Corporation of India) for the maturity corresponding to the expected life of the call option. Accordingly,

Strictly Confidential Page 18 of 22



- continuous risk-free rate is calculated. The continuous risk-free rate is arrived at 4.27% as on January 10, 2022.
- 9.3. On the basis of above, the value of call option on stock of the Company is arrived at INR 13.81 as on January 11, 2022 (Refer Annexure-III).

9.4. Valuation of Straight Bond

- The present value of Straight Bond is calculated by discounting the cash flow (principal repayment amount in this case) using a suitable discounting factor. The discounting factor should represent a rate of return based on the characteristics of OCDs, its credit rating and the credibility of the issuer.
- The Management has informed us that, currently the borrowing rate of Shalimar is 14% for secured debt. The nature of OCDs being unsecured we have added a risk premium of 2% to arrive at a discounting rate of 16%.
- Based on above the present value of Straight Bond is arrived at INR 165.46 (Refer Annexure IV) as on January 11, 2022.
- 9.5. The fair value of OCDs is arrived by aggregating the fair value of call option and fair value of straight bond as arrived above. Thus, the fair value of OCDs is arrived at INR 180.00/- (rounded off) as on January 11, 2022 (Refer Annexure V).

10. Conversion Price

10.1. As per para 8.10, equity share price has been determined referring Regulation 164(1) of ICDR Regulations for determining the floor price of conversion of OCDs into equity shares. The value per share of the Company as per Regulation 164 (1) of ICDR Regulations is INR 113.43/- (refer Annexure II). The proposed Conversion Price is INR 180.00/- which is higher than the minimum floor price as determined and in compliance as per applicable provisions of the ICDR Regulations. Hence the conversion price for Rule 13(2)(h) of the Companies (Share Capital and Debentures) Rules, 2014 is INR 180.00/-.

<<this space is intentionally left blank>>

Strictly Confidential Page 19 of 22



11. Conclusion

- 11.1. The valuation conclusions arrived at many cases are by their nature subjective and dependent on the exercise of individual judgment. There can be therefore no standard formulae to establish an indisputable value, although certain formulae are helpful in assessing reasonableness.
- 11.2. The current valuation has been carried out based on the valuation methodology explained herein earlier. Further, various qualitative factors, the business dynamics and growth potential of the business, having regard to information base, management perceptions and limitations, were given due consideration.
- 11.3. The Fair Value as on the Valuation Date is determined as INR 180 for each OCD.
- 11.4. The floor price for conversion of OCDs into equity shares as on the Valuation Date is determined as INR 113.43/-. The proposed Conversion Price is INR 180.00/- which is higher than the minimum floor price and in compliance as per required provisions of ICDR Regulations. Hence the Conversion Price for the Rule 13(2)(h) of the Companies (Share Capital and Debentures) Rules, 2014 is INR 180/-.

<<this space is intentionally left blank>>

Strictly Confidential Page 20 of 22



12. Annexure

Annexure I: Volume of Frequently Traded Equity Shares

Particulars	NSE	BSE
No. of Shares Traded	78,628,613	13,127,523
Number of Shares Outstanding during the Aforesaid Period	54,300,259	54,300,259
Traded Volume (in %age)	144.8%	24.2%

Annexure II: Equity Share Price Calculation

1 January 10, 2022 117.20 111.80 114.50 102.17 113.43 2 January 3, 2022 115.10 109.62 112.36 3 December 27, 2021 114.26 107.12 110.69 4 December 20, 2021 108.34 104.98 106.66 5 December 13, 2021 108.25 105.83 107.04 6 December 6, 2021 105.46 102.36 103.91 7 November 29, 2021 111.41 101.39 106.40 8 November 22, 2021 111.17 103.56 107.37 9 November 15, 2021 97.05 95.53 96.29 10 November 8, 2021 91.18 90.59 90.89 11 November 1, 2021 94.10 91.12 92.61 12 October 25, 2021 94.98 90.16 92.57 13 October 18, 2021 97.87 97.06 97.47 14 October 11, 2021 97.87 97.06 97.47 15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38 26 July 26, 2021 115.92 109.87 112.90	S.no.	Weekly Ending Date	Weekly High of VWAP	Weekly Low of VWAP	Average	(NSE)	2 Weeks Average High/Low (NSE)
3 December 27, 2021 114.26 107.12 110.69 4 December 20, 2021 108.34 104.98 106.66 5 December 13, 2021 108.25 105.83 107.04 6 December 6, 2021 105.46 102.36 103.91 7 November 29, 2021 111.41 101.39 106.40 8 November 22, 2021 111.17 103.56 107.37 9 November 15, 2021 97.05 95.53 96.29 10 November 8, 2021 91.18 90.59 90.89 11 November 1, 2021 94.10 91.12 92.61 12 October 25, 2021 94.98 90.16 92.57 13 October 18, 2021 97.87 97.06 97.47 14 October 11, 2021 97.87 97.06 97.47 15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	1	January 10, 2022	117.20	111.80	114.50	102.17	113.43
4 December 20, 2021 108.34 104.98 106.66 5 December 13, 2021 108.25 105.83 107.04 6 December 6, 2021 105.46 102.36 103.91 7 November 29, 2021 111.41 101.39 106.40 8 November 22, 2021 111.17 103.56 107.37 9 November 15, 2021 97.05 95.53 96.29 10 November 8, 2021 91.18 90.59 90.89 11 November 1, 2021 94.10 91.12 92.61 12 October 25, 2021 94.98 90.16 92.57 13 October 18, 2021 97.87 97.06 97.47 14 October 11, 2021 97.87 97.06 97.47 15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	2	January 3, 2022	115.10	109.62	112.36		
5 December 13, 2021 108.25 105.83 107.04 6 December 6, 2021 105.46 102.36 103.91 7 November 29, 2021 111.41 101.39 106.40 8 November 22, 2021 111.17 103.56 107.37 9 November 15, 2021 97.05 95.53 96.29 10 November 8, 2021 91.18 90.59 90.89 11 November 1, 2021 94.10 91.12 92.61 12 October 25, 2021 94.98 90.16 92.57 13 October 18, 2021 97.91 96.46 97.19 14 October 4, 2021 97.87 97.06 97.47 15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 6, 2021 99.14 94.88 97.01 20 A	3	December 27, 2021	114.26	107.12	110.69		
6 December 6, 2021 105.46 102.36 103.91 7 November 29, 2021 111.41 101.39 106.40 8 November 22, 2021 111.17 103.56 107.37 9 November 15, 2021 97.05 95.53 96.29 10 November 8, 2021 91.18 90.59 90.89 11 November 1, 2021 94.10 91.12 92.61 12 October 25, 2021 94.98 90.16 92.57 13 October 18, 2021 97.91 96.46 97.19 14 October 11, 2021 97.87 97.06 97.47 15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	4	December 20, 2021	108.34	104.98	106.66		
7 November 29, 2021 111.41 101.39 106.40 8 November 22, 2021 111.17 103.56 107.37 9 November 15, 2021 97.05 95.53 96.29 10 November 8, 2021 91.18 90.59 90.89 11 November 1, 2021 94.10 91.12 92.61 12 October 25, 2021 94.98 90.16 92.57 13 October 18, 2021 97.91 96.46 97.19 14 October 11, 2021 97.87 97.06 97.47 15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 Aug	5	December 13, 2021	108.25	105.83	107.04		
8 November 22, 2021 111.17 103.56 107.37 9 November 15, 2021 97.05 95.53 96.29 10 November 8, 2021 91.18 90.59 90.89 11 November 1, 2021 94.10 91.12 92.61 12 October 25, 2021 94.98 90.16 92.57 13 October 18, 2021 97.91 96.46 97.19 14 October 4, 2021 97.87 97.06 97.47 15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August	6	December 6, 2021	105.46	102.36	103.91		
9 November 15, 2021 97.05 95.53 96.29 10 November 8, 2021 91.18 90.59 90.89 11 November 1, 2021 94.10 91.12 92.61 12 October 25, 2021 94.98 90.16 92.57 13 October 18, 2021 97.91 96.46 97.19 14 October 11, 2021 97.87 97.06 97.47 15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	7	November 29, 2021	111.41	101.39	106.40		
10 November 8, 2021 91.18 90.59 90.89 11 November 1, 2021 94.10 91.12 92.61 12 October 25, 2021 94.98 90.16 92.57 13 October 18, 2021 97.91 96.46 97.19 14 October 11, 2021 97.87 97.06 97.47 15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26	8	November 22, 2021	111.17	103.56	107.37		
11 November 1, 2021 94.10 91.12 92.61 12 October 25, 2021 94.98 90.16 92.57 13 October 18, 2021 97.91 96.46 97.19 14 October 11, 2021 97.87 97.06 97.47 15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	9	November 15, 2021	97.05	95.53	96.29		
12 October 25, 2021 94.98 90.16 92.57 13 October 18, 2021 97.91 96.46 97.19 14 October 11, 2021 97.87 97.06 97.47 15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	10	November 8, 2021	91.18	90.59	90.89		
13 October 18, 2021 97.91 96.46 97.19 14 October 11, 2021 97.87 97.06 97.47 15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	11	November 1, 2021	94.10	91.12	92.61		
14 October 11, 2021 97.87 97.06 97.47 15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	12	October 25, 2021	94.98	90.16	92.57		
15 October 4, 2021 97.43 93.17 95.30 16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	13	October 18, 2021	97.91	96.46	97.19		
16 September 27, 2021 96.31 90.58 93.45 17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	14	October 11, 2021	97.87	97.06	97.47		
17 September 20, 2021 97.53 94.53 96.03 18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	15	October 4, 2021	97.43	93.17	95.30		
18 September 13, 2021 101.43 97.07 99.25 19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	16	September 27, 2021	96.31	90.58	93.45		
19 September 6, 2021 99.14 94.88 97.01 20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	17	September 20, 2021	97.53	94.53	96.03		
20 August 30, 2021 95.32 93.61 94.47 21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	18	September 13, 2021	101.43	97.07	99.25		
21 August 23, 2021 104.19 96.14 100.17 22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	19	September 6, 2021	99.14	94.88	97.01		
22 August 16, 2021 104.07 99.79 101.93 23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	20	August 30, 2021	95.32	93.61	94.47		
23 August 9, 2021 110.82 107.69 109.26 24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	21	August 23, 2021	104.19	96.14	100.17		
24 August 2, 2021 109.68 107.10 108.39 25 July 26, 2021 113.11 111.64 112.38	22	August 16, 2021	104.07	99.79	101.93		
25 July 26, 2021 113.11 111.64 112.38	23	August 9, 2021	110.82	107.69	109.26		
	24	August 2, 2021	109.68	107.10	108.39		
26 July 19, 2021 115.92 109.87 112.90	25	July 26, 2021	113.11	111.64	112.38		
	26	July 19, 2021	115.92	109.87	112.90		

Strictly Confidential Page 21 of 22



Annexure III - Valuation of Call Option

Particulars	
Date of Valuation	January 11, 2022
Proportion of Vest (%)	100.0%
Price of the Underlying Stock (INR)	113.43
Exercise / Strike Price (INR)	180.00
Expected Time to Expiration (years)	1.50
Volatility (%)	51.8%
Continuous Risk-free Interest Rate (%)	4.27%
Expected Dividend (%)	0.00%
Value of Call Option (INR)	13.81

Annexure IV - Valuation of Straight Bond

INR

Particulars	April 11, 2022	July 11, 2022	October 11, 2022	January 11, 2023	April 11, 2023	July 11, 2023
Total Cash Flows	4.05	4.05	4.05	4.05	4.05	4.05
Redemption Cash Flow						180.00
Total Cash Flows	4.05	4.05	4.05	4.05	4.05	184.05
Present Value Factor	0.96	0.93	0.89	0.86	0.83	0.80
Present Value of Cash Flows	3.90	3.76	3.62	3.49	3.36	147.32
Value per Straight Bond	165.46					

Annexure V - Summary

INR

Particulars	Amount
Value of Call Option (INR)	13.81
Value of Straight bond (INR)	165.46
Value of OCD (INR)	179.26
Fair Value of OCD - (INR) (Rounded Off)	180.00

<<this space is intentionally left blank>>

Strictly Confidential Page 22 of 22